Toggle light / dark theme

Asteroids are coming?


The asteroid, dubbed 2019 WR3, has been directly observed some 74 times by NASA since it was spotted in the skies on November 27, so the space agency could calculate its size, speed and trajectory, and determine the threat level.

NASA now believes the space rock measures between 76 and 170 meters (249 and 557 feet) and is travelling at speeds of 27,036kph (16,799mph).

Big tech firms are investing in data centers as they compete for the $214 billion cloud computing market. WSJ explains what cloud computing is, why big tech is betting big on future contracts.

More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Visit the WSJ Video Center: https://wsj.com/video

On Facebook: https://www.facebook.com/pg/wsj/videos/
On Twitter: https://twitter.com/WSJ
On Snapchat: https://on.wsj.com/2ratjSM

#WSJ #Amazon #Microsoft

In pouring over data from Australia’s Desert Fireball Network (DFN) — a network of cameras set up across Australia to capture images of minimoon fireballs, or minimoons entering Earth’s atmosphere and burning up — a group of researchers have identified what they think is a minimoon meteor, or fireball.

This is the second time that researchers have identified a TCO blazing through the atmosphere before hitting the ground. In finding the fireball, named DN160822_03, the researchers think that it exploded over the Australian desert on Aug. 22, 2016.

Related: Earth Has ‘Minimoons,’ and They May Solve Asteroid Mysteries.

Researchers in Vienna from Ulrich Elling’s laboratory at IMBA—Institute of Molecular Biotechnology of the Austrian Academy of Sciences—in collaboration with the Vienna BioCenter Core Facilities have developed a revolutionary CRISPR technology called “CRISPR-Switch,” which enables unprecedented control of the CRISPR technique in both space and time.

CRISPR/Cas9 technology is based on a modified version of a bacterial defense system against bacteriophages. One of the landmark discoveries for this technique in fact was laid in Vienna and published in 2012 in a study co-authored by Emmanuelle Charpentier and VBC Ph.D. student, Krzysztof Chylinski. Due to its power to also edit mammalian genomes, CRISPR/Cas9 has rapidly established itself as the most employed gene editing method in laboratories across the world with huge potential to find its way to the clinics to cure rare disease. Just a week ago, the first success in the treatment of sickle cell anemia was announced.

To control the power of genome editing, several groups have worked on systems to control editing activity. Scientists from the lab of Ulrich Elling at IMBA were now able to gain unprecedented control over sgRNA activity, in a system termed “CRISPR-Switch.” The results are published in the renowned journal Nature Communications.